Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
Venus Remedies is currently trading at Rs 185.00, down by 1.60 points or 0.86% from its previous closing of Rs 186.60 on the BSE.
The scrip opened at Rs 188.85 and has touched a high and low of Rs 189.75 and Rs. 183.10 respectively. So far 2769 shares were traded on the counter.
The BSE group 'B' stock of face value Rs 10 has touched a 52 week high of Rs 300.00 on 16-Nov-2010 and a 52 week low of Rs 176.20 on 20-Jun-2011.
Last one week high and low of the scrip stood at Rs 210.00 and Rs 183.10 respectively. The current market cap of the company is Rs 170.59 crore.
The promoters holding in the company stood at 30.42% while Institutions and Non-Institutions held 16.35% and 53.23% respectively.
Mid-sized drug maker, Venus Remedies has received approval for market authorization from MHRA (UK) via DCP route ( which covers Ireland, Poland, Slovenia, Netherlands, Finland, Austria, Slovakia, Denmark, Germany, Sweden, France and Italy also) for its generic board spectrum injectable antibiotic carbapenem. The company is all set to launch this drug soon within this fiscal year. Besides, this Venus has also got market authorization for the same product from New Zealand’s Ministry of Health.
Market authorization grants from both territories have opened doors for Venus to enter into the highly lucrative penems market of $250 million in Europe and $20 million in New Zealand. Meropenem market authorization grants once again proved company’s R&D capabilities and its expertise in developing world class products with regulatory might.
Meropenem is a broad spectrum anti-bacterial agent of carbapenem family indicated as empirical therapy prior to the identification of causative organism, or for disease caused by single or multiple susceptible bacteria in both adults and children with a broad range of serious infections. At present, Meropenem sales accounts for $906 million across the globe, which is estimated to grow to $1,006 million by 2012.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1532.20 |
| Dr. Reddys Lab | 5820.00 |
| Cipla | 1423.85 |
| Zydus Lifesciences | 1008.15 |
| Lupin | 1659.15 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
